Intellia Therapeutics News

Latest Intellia Therapeutics Stock News & NTLA Headlines

Intellia Therapeutics, Inc. (NTLA) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE Transcript

3 days ago | seekingalpha.com

Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026

4 days ago | globenewswire.com

Intellia: Quiet Q3 Earnings As All Eyes Turn To March 2027 Approval Decision

9 days ago | seekingalpha.com

Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus

9 days ago | zacks.com

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates

10 days ago | zacks.com

Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

11 days ago | globenewswire.com

Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)

12 days ago | globenewswire.com

Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations

13 days ago | globenewswire.com

Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026

18 days ago | globenewswire.com

Intellia Therapeutics (NASDAQ:NTLA) and Neurogene (NASDAQ:NGNE) Critical Survey

a month ago | defenseworld.net

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

Market Closed

NTLA

Intellia Therapeutics

$ 9.70

-8.06%

Last 24H

Trading with leverage comes with a high risk and may not be suitable for everyone.

Portfolio

Updated 2 days ago

Top

Gainers

Losers

Symbol

Last Price

24H CNG

Intellia Therapeutics News

Latest Intellia Therapeutics Stock News & NTLA Headlines

Download App

People Also Watch

Explore our Tools